Status and phase
Conditions
Treatments
About
This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55 patients is planned for enrollment. The time for enrollment is from Nov 2017 to Nov 2020, the the follow-up will be ended after Nov 2021. Patients in the study would receive oral apatinib 500-750mg qd until progression of disease.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
55 participants in 1 patient group
Loading...
Central trial contact
Chenchen Wang, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal